Compass

Compass is a biopharmaceutical company developing treatments for depression and other diseases, and it also operates a consent infrastructure platform called NodGuard.

Why it’s in the news: It is in the news due to its announcement that a depression drug has long-lasting benefits and the launch of its new NodGuard service.

Latest on Compass

• STAT+: Compass says depression drug has long-lasting benefits
• Compass launches NodGuard: Consent infrastructure that connects compliance to marketing performance
• STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
• VC funding dries in May; Fertility treatment with compassion
• Love and compassion in China: Moroccan student saves drowning woman, long-ago pen pals reunite
• Turning urgency into opportunity: The CIO as a compass in an AI-first world
• 13F: Nixon Capital Llc holds Compass ($37M)

Connections

3 entities linked to Compass across the news graph.